Valodip 5mg/80mg 30 tablets — Made in Slovenia — Free Delivery

Valodip tablets are indicated for essential hypertension in adult patients whose blood pressure is not regulated by amlodipine or valsartan monotherapy.

Active ingredient: amlodipine in the form of amlodipine besylate, valsartan;

1 coated tablet contains 5 mg of amlodipine in the form of amlodipine besilate and 80 mg of valsartan, or 5 mg of amlodipine in the form of amlodipine besilate and 160 mg of valsartan, or 10 mg of amlodipine in the form of amlodipine besilate and 160 mg of valsartan;

Excipients: microcrystalline cellulose, mannitol (E 421), magnesium stearate, croscarmellose sodium, povidone, colloidal silicon dioxide, sodium lauryl sulfate;

Film coat: polyvinyl alcohol (partially hydrolysed), titanium dioxide (E 171), polyethylene glycol 3000, talc, iron oxide yellow (E 172).

Hypersensitivity to the active substance, dihydropyridine derivatives or any of the excipients of the drug.

Severe liver dysfunction, biliary cirrhosis or cholestasis.

Simultaneous use of angiotensin receptor antagonists (ARA), including valsartan, or ACE inhibitors (ACE) with aliskiren in patients with diabetes mellitus or with impaired renal function (glomerular filtration rate.

Contraindicated in pregnant women and women planning pregnancy.

severe hypotension.

Shock (including cardiogenic shock).

Obstruction of the outflow tract of the left ventricle (for example, hypertrophic obstructive cardiomyopathy and severe aortic stenosis).

Hemodynamically unstable heart failure after acute myocardial infarction.

Patients whose blood pressure is not adequately controlled with amlodipine or valsartan alone can be treated with preparation combination therapy. The recommended dose is 1 tablet per day. The tablets can be taken with or without food, with a small amount of water.

Patients taking valsartan and amlodipine separately can be prescribed a preparation that contains the same doses of the components.

Before using the combination, it is recommended to individually adjust the doses of the individual components (i.e. amplodipine and valsartan). In case of clinical need, direct replacement of monotherapy with a combination of fixed doses can be considered.

Contraindicated.

Not recommended.

With caution, dizziness is possible.

Symptoms. At present, there is no experience of preparation overdose. The main symptom of an overdose of valsartan is probably severe arterial hypotension with dizziness. An overdose of amlodipine can lead to progressive peripheral vasodilation and possibly reflex tachycardia. Significant prolonged systemic hypotension, up to shock and death, has been reported.

Treatment. If the preparation has been used recently, induce vomiting or gastric lavage. The absorption of amlodipine is significantly reduced when activated charcoal is used immediately or within two hours after taking amlodipine.

Adverse reactions that were observed most often or were significant or severe: nasopharyngitis, influenza, hypersensitivity, headache, syncope, orthostatic hypotension, edema, soft tissue edema, facial edema, peripheral edema, increased fatigue, facial flushing, asthenia and hot flashes.

Interaction studies with other medicinal products have not been conducted.

Grapefruit or grapefruit juice. The use of amlodipine with grapefruit juice or with grapefruit is not recommended, since in some patients the bioavailability may be increased, which will lead to an increase in the hypotensive effect of the drug.

Store below 30°C.

Keep out of the reach of children.

Shelf life - 3 years.